Inactive Instrument

Prevail Therapeutics Inc.

Equities

PRVL

US74140Y1010

Biotechnology & Medical Research

Prevail Therapeutics, Inc. Appoints Francois Nader to its Board of Directors

May 24, 2018 at 10:36 am EDT

Prevail Therapeutics, Inc. announced the appointment of Francois Nader, M.D., to its Board of Directors. He currently serves as Chairman of the Board of Directors of Acceleron Pharma and as Board Director of Alexion Pharmaceuticals and Clementia Pharmaceuticals.

Latest news about Prevail Therapeutics Inc.

Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	Apr. 16	CI
Scribe Therapeutics Inc. announced that it expects to receive $75 million in funding from Prevail Therapeutics Inc.	23-05-15	CI
Prevail Therapeutics Inc. Announces Board Resignations	21-01-22	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from S&P TMI Index	21-01-22	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from S&P Global BMI Index	21-01-22	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from NASDAQ Composite Index	21-01-22	CI
Eli Lilly and Company completed the acquisition of Prevail Therapeutics Inc. from Pontifax Ltd., OrbiMed Advisors LLC and others.	21-01-21	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from NASDAQ Biotechnology Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2000 Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 3000 Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2500 Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2000 Growth Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell Small Cap Completeness Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell Small Cap Comp Growth Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 3000 Growth Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2500 Growth Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell Microcap Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 3000E Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 3000E Growth Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell Microcap Growth Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2000 Dynamic Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2500 Dynamic Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2000 Growth-Dynamic Index	21-01-20	CI
Prevail Therapeutics Inc.(NasdaqGM:PRVL) dropped from Russell 2500 Growth-Dynamic Index	21-01-20	CI
Nasdaq ends at record high on stimulus bets, Apple boost	20-12-15	RE

Chart Prevail Therapeutics Inc.

Duration

Period

More charts

Company Profile

Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company's lead program is PR001 for the treatment of Parkinson's disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.44%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-6.77%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs